File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three

TitleGlobal variations in prevalence of eczema symptoms in children from ISAAC Phase Three
Authors
Issue Date2009
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/jaci
Citation
Journal of Allergy and Clinical Immunology, 2009, v. 124 n. 6, p. 1251-1258.e23 How to Cite?
AbstractBACKGROUND: In 1999, The International Study of Asthma and Allergies in Childhood (ISAAC) Phase One reported the prevalence of eczema symptoms in 715,033 children from 154 centers in 56 countries by using standardized epidemiologic tools. OBJECTIVE: To update the world map of eczema prevalence after 5 to 10 years (ISAAC Phase Three) and include additional data from over 100 new centers. METHODS: Cross-sectional surveys using the ISAAC questionnaire on eczema symptoms were completed by adolescents 13 to 14 years old and by parents of children 6 to 7 years old. Current eczema was defined as an itchy flexural rash in the past 12 months and was considered severe eczema if associated with 1 or more nights per week of sleep disturbance. RESULTS: For the age group 6 to 7 years, data on 385,853 participants from 143 centers in 60 countries showed that the prevalence of current eczema ranged from 0.9% in India to 22.5% in Ecuador, with new data showing high values in Asia and Latin America. For the age group 13 to 14 years, data on 663,256 participants from 230 centers in 96 countries showed prevalence values ranging from 0.2% in China to 24.6% in Columbia with the highest values in Africa and Latin America. Current eczema was lower for boys than girls (odds ratio, 0.94 and 0.72 at ages 6 to 7 years and 13 to 14 years, respectively). CONCLUSION: ISAAC Phase Three provides comprehensive global data on the prevalence of eczema symptoms that is essential for public health planning. New data reveal that eczema is a disease of developing as well as developed countries.
Persistent Identifierhttp://hdl.handle.net/10722/207673
ISSN
2015 Impact Factor: 12.485
2015 SCImago Journal Rankings: 5.513

 

DC FieldValueLanguage
dc.contributor.authorOdhiambo, JA-
dc.contributor.authorWilliams, HC-
dc.contributor.authorClayton, TO-
dc.contributor.authorRobertson, CF-
dc.contributor.authorAsher, MI-
dc.contributor.authorISSAC Phase Three Study Group,-
dc.contributor.authorLau, YL-
dc.date.accessioned2015-01-13T02:46:08Z-
dc.date.available2015-01-13T02:46:08Z-
dc.date.issued2009-
dc.identifier.citationJournal of Allergy and Clinical Immunology, 2009, v. 124 n. 6, p. 1251-1258.e23-
dc.identifier.issn0091-6749-
dc.identifier.urihttp://hdl.handle.net/10722/207673-
dc.description.abstractBACKGROUND: In 1999, The International Study of Asthma and Allergies in Childhood (ISAAC) Phase One reported the prevalence of eczema symptoms in 715,033 children from 154 centers in 56 countries by using standardized epidemiologic tools. OBJECTIVE: To update the world map of eczema prevalence after 5 to 10 years (ISAAC Phase Three) and include additional data from over 100 new centers. METHODS: Cross-sectional surveys using the ISAAC questionnaire on eczema symptoms were completed by adolescents 13 to 14 years old and by parents of children 6 to 7 years old. Current eczema was defined as an itchy flexural rash in the past 12 months and was considered severe eczema if associated with 1 or more nights per week of sleep disturbance. RESULTS: For the age group 6 to 7 years, data on 385,853 participants from 143 centers in 60 countries showed that the prevalence of current eczema ranged from 0.9% in India to 22.5% in Ecuador, with new data showing high values in Asia and Latin America. For the age group 13 to 14 years, data on 663,256 participants from 230 centers in 96 countries showed prevalence values ranging from 0.2% in China to 24.6% in Columbia with the highest values in Africa and Latin America. Current eczema was lower for boys than girls (odds ratio, 0.94 and 0.72 at ages 6 to 7 years and 13 to 14 years, respectively). CONCLUSION: ISAAC Phase Three provides comprehensive global data on the prevalence of eczema symptoms that is essential for public health planning. New data reveal that eczema is a disease of developing as well as developed countries.-
dc.languageeng-
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/jaci-
dc.relation.ispartofJournal of Allergy and Clinical Immunology-
dc.rightsNOTICE: this is the author’s version of a work that was accepted for publication in [Journal title]. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in PUBLICATION, [VOL#, ISSUE#, (DATE)] DOI#-
dc.subject.meshCross-Sectional Studies-
dc.subject.meshEczema - epidemiology-
dc.subject.meshGlobal Health-
dc.subject.meshPrevalence-
dc.subject.meshQuestionnaires-
dc.titleGlobal variations in prevalence of eczema symptoms in children from ISAAC Phase Threeen_US
dc.typeArticleen_US
dc.identifier.emailLau, YL: lauylung@hkucc.hku.hk-
dc.identifier.doi10.1016/j.jaci.2009.10.009-
dc.identifier.pmid20004783-
dc.identifier.hkuros170388-
dc.identifier.volume124-
dc.identifier.issue6-
dc.identifier.spage1251-
dc.identifier.epage1258.e23-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats